Immune Design (IMDZ) Misses Q4 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
- Piper Sandler Starts SoFi Technologies (SOFI) at Overweight
Jefferies Cuts Price Target on Immune Design (IMDZ) Following 4Q
March 11, 2016 9:29 AM ESTJefferies maintained a Buy rating on Immune Design (NASDAQ: IMDZ), and cut the price target to $21.00 (from $23.00), following the company's 4Q earnings report. 4Q operating expenses were $13.3M consisting of $8.9M of R&D. This contributed to a net loss of $12.1M compared to... More
